Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575105 | 0.90 | PTGDR2 (0.53) | PTGDR2PTGS2PTGS1 | |
| SCHEMBL2772075 | 0.87 | PTGDR2 (0.38) | PTGDR2PTGS2PTGS1FNTAFNTB | |
| SCHEMBL4635720 | 0.85 | PTGS2 (0.39) | PTGDR2PTGS2PTGS1HCRTR2SLC6A9 | |
| SCHEMBL2770310 | 0.84 | PTGDR2 (0.54) | PTGDR2PTGS2PTGS1GAA | |
| SCHEMBL2769710 | 0.80 | PTGDR2 (0.66) | PTGDR2PTGS2PTGS1GAA | |
| SCHEMBL2768379 | 0.76 | PTGDR2 (0.48) | PTGDR2 | |
| SCHEMBL4635352 | 0.76 | PTGS2 (0.40) | PTGDR2PTGS2PTGS1AR | |
| SCHEMBL2769893 | 0.74 | PTGDR2 (0.44) | PTGDR2PTGS2PTGS1HCRTR2 | |
| SCHEMBL4636239 | 0.74 | PTGDR2 (0.35) | PTGDR2PTGS2PTGS1FNTAFNTB | |
| SCHEMBL4635729 | 0.73 | SLC6A9 (0.34) | PTGDR2PTGS2SLC6A9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010034-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| EP-2094266-A1 | CRTH2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074966-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010034-A1 | CRTH2 ANTAGONISTS | HRH2, MDH2, HRH1 | PTGDR2 167/4885PTGS2 426/4885PTGS1 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.